Fitxers

Alcohol-associated liver disease.pdf (1.36 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-02-01

Llicència de publicació

cc-by-nc-nd (c) Hernandez Evole, Helena et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227438

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3350/cmh.2024.0709

Resum

Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules. (Clin Mol Hepatol 2025;31(Suppl):S112-S133)

Matèries

Hepatopaties alcohòliques, Malalties del fetge, Consum d'alcohol

Matèries (anglès)

Alcoholic liver diseases, Liver diseases, Drinking of alcoholic beverages

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ALVARADO TAPIAS, Edilmar, et al. Alcohol-associated liver disease: Natural history, management and novel targeted therapies. Clinical And Molecular Hepatology. 2023. Vol. 29, num. 1. ISSN 1665-2681. [consulted: 21 of May of 2026]. Available at: https://hdl.handle.net/2445/227438

Exportar metadades

JSON - METS

Compartir registre